NCT01110018View on ClinicalTrials.gov

GSK573719 IV Enabling Study

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 28, 2010

Primary Completion Date

June 9, 2010

Study Completion Date

June 9, 2010

Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
DRUG

GSK573719 (SOLUTION)

20μg /mL solution for IV and Oral dosing

DRUG

GSK573719 (INHALATION POWDER)

500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).

Trial Locations (1)

NW10 7EW

GSK Investigational Site, London

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY